Corcept Therapeutics (CORT) Tops Q1 EPS by 3c, increases guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.22 -3.31%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of $0.25, $0.03 better than the analyst estimate of $0.22. Revenue for the quarter came in at $146.81 million versus the consensus estimate of $141.19 million.
GUIDANCE:
Corcept Therapeutics sees FY2024 revenue of $620-650 million, versus the consensus of $610.6 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Miller Industries (MLR) Misses Q3 EPS by 11c, Misses on Revenue; Offers FY26 Revenue Guidance
- Curtiss-Wright (CW) Tops Q3 EPS by 17c; offers guidance
- Fastly, Inc. (FSLY) Tops Q3 EPS by 5c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
